The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1609
October 19, 2020
View Complete Issue         Table of Contents 2019 
Caplacizumab (Cablivi) for iTTP
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Caplacizumab (Cablivi) for iTTP
October 19, 2020 (Issue: 1609)
Caplacizumab-yhdp (Cablivi – Sanofi /Genzyme), a von Willebrand factor-directed antibody fragment, has been approved by the FDA for use in combination with plasma exchange and immunosuppressive therapy for treatment of immune-mediated...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Caplacizumab (Cablivi) for iTTP
Article code: 1609c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.